JAMES BIESINGER: Open Payments
NPI 1205885472 · PROVO, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,171 in 213 payments from 19 companies in 2025. Trend: 2023 $1,709 · 2024 $2,814 · 2025 $3,171
Food & beverage: $3,094Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 52 | $770 |
| Janssen Biotech, Inc. | 28 | $481 |
| Aimmune Therapeutics, Inc. | 19 | $300 |
| PFIZER INC. | 44 | $288 |
| Ardelyx, Inc. | 13 | $244 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $193 |
| Celltrion USA Inc. | 8 | $189 |
| Madrigal Pharmaceuticals | 9 | $175 |
| Phathom Pharmaceuticals, Inc. | 9 | $137 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $87 |
Products named: TREMFYA, RINVOQ, IBSRELA, ZENPEP, XELJANZ, ENTYVIO, VEGZELMA, REZDIFFRA.
Industry payments across UT — which companies pay providers there.
